Literature DB >> 3061467

The asymmetric dimeric polymerase hypothesis: a progress report.

C S McHenry1.   

Abstract

In 1983, my laboratory first proposed that the DNA polymerase III holoenzyme is an asymmetric dimer with distinguishable leading and lagging strand polymerases. Here, I review progress by my laboratory and others in testing this hypothesis. To date, the hypothesis is supported by our demonstration of (i) an asymmetry in function of two populations of holoenzyme in solution in their ability to use the ATP analog, ATP gamma S, to support initiation complex formation, (ii) the stabilization of a dimeric polymerase structure by the tau subunit, (iii) allosteric communication between polymerase halves and (iv) the coexistence of gamma and the tau, subunits which share common sequences, within the same holoenzyme assemblies. This latter observation may provide a structural basis for holoenzyme asymmetry. I discuss the implications of the asymmetric dimer hypothesis to the solution of problems encountered by polymerases at the replication fork and delineate further tests required before the hypothesis can be firmly established.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3061467     DOI: 10.1016/0167-4781(88)90092-9

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  3 in total

1.  Transient mutators: a semiquantitative analysis of the influence of translation and transcription errors on mutation rates.

Authors:  J Ninio
Journal:  Genetics       Date:  1991-11       Impact factor: 4.562

2.  The gamma subunit of DNA polymerase III holoenzyme of Escherichia coli is produced by ribosomal frameshifting.

Authors:  A M Flower; C S McHenry
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

3.  Crystal structure and mode of helicase binding of the C-terminal domain of primase from Helicobacter pylori.

Authors:  Syed Arif Abdul Rehman; Vijay Verma; Mohit Mazumder; Suman K Dhar; S Gourinath
Journal:  J Bacteriol       Date:  2013-04-12       Impact factor: 3.490

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.